AzTrials
AzTrials

Functional Constipation in Children Ages 6-17 YearsPhase 2NCT02559570

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

A Phase 2 study testing LIN Dose A, LIN Dose B and LIN Dose C in people with Functional Constipation in Children Ages 6-17 Years, run by Forest Laboratories at 62 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study was to evaluate dose response of the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children age 6-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Read more about this study

Who is it for?
Ages 6 to 17 years
What is being tested?
LIN Dose A, LIN Dose B and LIN Dose C
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
173 participants
Where
62 sitesin 2 countries
Study dates
3 Nov 2015to 29 May 2018
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Participant weighs at least 18 kg (kilograms) (39.7 lbs)
  • Participant meets modified Rome III criteria for child/adolescent FC: For at least 2 months before the Screening Visit, the participant has had 2 or fewer defecations (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours) in the toilet per week. In addition, at least once per week, patient meets 1 or more of the following:
  • a) History of retentive posturing or excessive volitional stool retention
  • b) History of painful or hard bowel movements (BMs)
  • c) Presence of a large faecal mass in the rectum
  • d) History of large diameter stools that may obstruct the toilet
Show all 10Show fewer
  • e) At least one episode of fecal incontinence per week
  • Participant is willing to discontinue any laxatives used before the Pretreatment Visit in favor of the protocol-permitted rescue medicine
  • Participant has an average of fewer than 3 spontaneous BMs (SBMs) per week during the 14 days before the randomization day and up to the randomization. An SBM is defined as a BM that occurs in the absence of laxative, enema, or suppository use on the calendar day of the BM or the calendar day before the BM
  • Participant or participant/guardian/legally authorized representative (LAR) or caregiver is compliant with electronic diary (eDiary) by completing both the morning and evening assessments for 10 out of the 14 days immediately preceding the Randomization Visit

Who cannot join

  • Participant meets Rome III criteria for Child/Adolescent irritable bowel syndrome (IBS): At least once per week for at least 2 months before the Screening Visit, the participant has experienced abdominal discomfort (an uncomfortable sensation not described as pain) or pain associated with 2 or more of the following at least 25% of the time:
  • 1. Improvement with defecation
  • 2. Onset associated with a change in frequency of stool
  • 3. Onset associated with a change in form (appearance) of stool
  • Participant reports having more than 1 loose, mushy stool (eDiary-recorded stool consistency of 6 on the Pediatric Bristol Stool Form Scale [p-BSFS]) or any watery stool (eDiary-recorded stool consistency of 7 on the p-BSFS) with any SBM that occurred in the absence of laxative use on the calendar day of the BM or the calendar day before the BM during the 14 days before the randomization day and up to the randomization
  • Select medical history or conditions that may be related to other causes of constipation or may interfere with safety and efficacy analyses
  • Participant has required manual or hospital-based disimpassion any time prior to randomization
  • Participant is unable to tolerate the placebo during the Screening Period

Trial locations and contacts

62 sites in 2 countries.

62 sites in 2 countries

United States60 sites
  • Advanced Research Center

    Anaheim, California, 92805

  • Asheboro Research Associates

    Asheboro, North Carolina, 27203

  • Children's Center for Digestive Health Care LLC

    Atlanta, Georgia, 30342

  • University of Maryland Children's Hospital

    Baltimore, Maryland, 21201

  • Kentucky Pediatric/ Adult Research

    Bardstown, Kentucky, 40004

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

  • Craig A. Speigel, MD

    Bridgeton, Missouri, 63044

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599

  • Coastal Pediatric Research

    Charleston, South Carolina, 29414

  • Colorado Springs Health Partners, HCP-Clinical Research, LLC

    Colorado Springs, Colorado, 80922

  • Kindred Medical Institute for Clinical Trials, LLC

    Corona, California, 92879

  • WCCT Global, LLC

    Costa Mesa, California, 92626

  • Ohio Pediatric Research Association

    Dayton, Ohio, 45414

  • Pediatric Specialists of Virginia

    Fairfax, Virginia, 22031

  • Nova Southeastern University

    Fort Lauderdale, Florida, 33314

  • Cook Children's Medical Center

    Fort Worth, Texas, 76104

  • Homestead Research Institute

    Homestead, Florida, 33030

  • RM Medical Research

    Homestead, Florida, 33030

  • HealthStar Research, LLC

    Hot Springs, Arkansas, 71913

  • Texas Children's Hospital/Baylor College Medicine

    Houston, Texas, 77030

  • Houston Clinical Research Associates

    Houston, Texas, 77090

  • Riley Hospital for Children at Indiana University Health

    Indianapolis, Indiana, 46202

  • GI Associates and Endoscopy Center

    Jackson, Mississippi, 39232

  • Pediatric Care Specialists

    Johnstown, Pennsylvania, 15904

  • Midwest Children Health Research Institute

    Lincoln, Nebraska, 68505

  • Midwest Children Health Research Institute

    Lincoln, Nebraska, 68516

  • Applied Research Center of Arkansas

    Little Rock, Arkansas, 72212

  • Ark Clinical Research

    Long Beach, California, 90806

  • ACTCA, Inc

    Los Angeles, California, 90017

  • Children's Hospital Los Angeles

    Los Angeles, California, 90017

  • Kosair Children's Hospital - Pediatric Clinical Research Unit

    Louisville, Kentucky, 40202

  • Advanced Medical Research Center

    Miami, Florida, 33135

  • University Of Minnesota

    Minneapolis, Minnesota, 55455

  • Goryeb Children's Hospital

    Morristown, New Jersey, 07962

  • Coastal Pediatrics Associates

    Mt. Pleasant, South Carolina, 29464

  • Columbia University Medical Center and Morgan Stanley

    New York, New York, 10032

  • Michael W. Simon, MD, PSC

    Nicholasville, Kentucky, 40356

  • IPS Research Company

    Oklahoma City, Oklahoma, 73103

  • Orange County Research Institute

    Ontario, California, 91762

  • Center for Clinical Trials, LLC

    Paramount, California, 90723

  • St. Christopher's Hospital for Children

    Philadelphia, Pennsylvania, 19134

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania, 15224

  • Preferred Primary Care Physicians, Inc.

    Pittsburgh, Pennsylvania, 15236

  • Rhode Island Hospital

    Providence, Rhode Island, 02903

  • Capital Pediatrics and Adolescent Center PLLC

    Raleigh, North Carolina, 27609

  • Virginia Tech Carilion School of Medicine Pediatric

    Roanoke, Virginia, 24013

  • Foothill Family Clinic South / J. Lewis Research, Inc.

    Salt Lake City, Utah, 84121

  • Sun Research Institute

    San Antonio, Texas, 78215

  • Southwest Children's Research Associates, P.A.

    San Antonio, Texas, 78229

  • UCSD Rady Children's Hospital

    San Diego, California, 92123

  • University of California at San Francisco

    San Francisco, California, 94143

  • Frontier Clinical Research, LLC

    Scottdale, Pennsylvania, 15683

  • Seattle Children's Hospital

    Seattle, Washington, 98105

  • Willis-Knighton Physician Network

    Shreveport, Louisiana, 71118

  • Montgomery Medical Inc.

    Smithfield, Pennsylvania, 15478

  • SCORE Physician Alliance, LLC

    St. Petersburg, Florida, 33710

  • Sleepcare Clinical Research Institute

    Stockbridge, Georgia, 30281

  • Ventura Clinical Trials

    Ventura, California, 93003

  • ClinPoint Trials

    Waxahachie, Texas, 75165

  • Heartland Research Associates, LLC

    Wichita, Kansas, 67205

Other trials in United States

Canada2 sites
  • Stollery Children's Hospital

    Edmonton, Alberta, T6G 2B7

  • Children's Hospital of Western Ontario

    London, Ontario, N6A 4G5

Other trials in Canada

About this study

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

The purpose of this study was to evaluate dose response of the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children age 6-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Participants age 6-11 years will receive oral liquid formulation and participants 12-17 years will receive solid oral capsule or liquid oral solution.

Children ages 6-11 years meeting the entry criteria will be randomized to 1 of 3 doses of linaclotide or placebo for 4 weeks. Children ages 12-17 years meeting the entry criteria will be randomized to 1 of 4 doses of linaclotide or placebo for 4 weeks.

This 4-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of FC.

Being tested
Placebo, LIN Dose A, LIN Dose B, LIN Dose C, LIN 145 µg
Keywords
Functional constipation in children, LINZESS

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDrug

    Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.

  • LIN Dose ADrug

    Also called LINZESS

    Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.

  • LIN Dose BDrug

    Also called LINZESS

    Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.

  • LIN Dose CDrug

    Also called LINZESS

    Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.

  • LIN 145 µgDrug

    Also called LINZESS

    Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.

Study groups in NCT02559570
Study groupRoleWhat they receive
PlaceboPlacebo comparatorParticipants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age.
Receives: Drug: Placebo
LIN Dose A (9 ug or 18 ug)ExperimentalParticipants aged 6 to 11 years with weight 18 to <35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
Receives: Drug: LIN Dose A
LIN Dose B (18 ug or 36 ug)ExperimentalParticipants aged 6 to 11 years with weight 18 to <35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
Receives: Drug: LIN Dose B
LIN Dose C (36 ug or 72 ug)ExperimentalParticipants aged 6 to 11 years with weight 18 to <35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
Receives: Drug: LIN Dose C
LIN 145 µgExperimentalParticipants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
Receives: Drug: LIN 145 µg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline (CFB) in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate During the Treatment Period

    SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. SBM rate was defined as SBMs/week during the 4-week Treatment period. Participants recorded the occurrence of BMs and use of rescue medication, morning and evening, daily in an eDiary since pretreatment period. The SBM frequency rate (SBMs/week) during the analysis period for each participant were calculated as [(total number of SBMs in the analysis period/number of days in the analysis period)*7]. Baseline value was based on values collected 14 days before randomization up to randomization. Change from Baseline was calculated as the SBM frequency rate during the 4-week treatment period - SBM frequency rate at baseline. A positive change from Baseline indicates improvement. Least squares mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) method.

    Measured: Baseline (14-day prior to randomization and up to randomization) to Week 4

Secondary outcomes (6)
  1. Change From Baseline (CFB) in 4-week Daytime Abdominal Pain

    The abdominal pain score was measured using 5-point scale. Participants answered the questions, How much did your tummy hurt as: 0=none, 1=a tiny bit, 2=a little, 3=some, and 4=a lot. The 4-week daytime abdominal pain was calculated as the average of nonmissing scores in evening eDiary during the Treatment Period with higher value indicating greater symptom severity. Baseline value was the average of non-missing values collected 14 days before randomization. Change from Baseline was calculated as the daytime abdominal pain score during the 4-week treatment period (i.e. average of non-missing daytime scores during 4-week treatment period) - daytime abdominal pain score at baseline. A negative change from Baseline indicates improvement. LSM and SE were calculated using ANCOVA method.

    Measured: Baseline (14-day prior to randomization) to Week 4

  2. Change From Baseline (CFB) in 4-week Stool Consistency

    Participants used 7-point pediatric Bristol Stool Form (p-BSFS) scale to rate stool consistency for each BM in morning and evening eDiary where 1=small hard lumps or balls like pebbles,2=fat sausage shape but lumpy and hard,3=a sausage but with cracks on it,4=sausage or snake, smooth and soft,5=chicken nuggets, soft smooth blobs,6=oatmeal, fluffy mushy pieces,7=milkshake, watery. Scores in 4-week treatment period were calculated by 2 approaches-1) following derivation similar in earlier adult studies, mean of participants non-missing, SBM associated p-BSFS scores during 4-week treatment period (adult derivation),2) observed weighted average of daily p-BSFS scores during that period. Daily p-BSFS score was average of non-missing morning and/or evening assessments of p-BSFS score from SBMs reported by participants on that specific day. Baseline value was based on values collected 14 days before randomization up to randomization. LSM and SE were calculated using ANCOVA method.

    Measured: Baseline (14-day prior to randomization and up to randomization) to Week 4

  3. Change From Baseline (CFB) in 4-week of Severity of Straining

    Severity of straining was scored on 5-point scale for question-When you pooped, how hard did you push? The score ranges from 0= not hard at all,1= I pushed a tiny bit hard,2= I pushed a little hard,3= I pushed hard,4= I pushed very hard with higher scores indicating more severe straining. Participants recorded degree of straining for each BM in morning and evening eDiary. Data was derived as adult derivation and weighted average. Scores during 4-week treatment period were calculated following two approaches - (1) following derivation similar in earlier adult studies, as mean of participant's non-missing, SBM associated straining scores during 4-week treatment period (adult derivation) and (2) as observed weighted average of daily straining scores during that period. Daily straining score was the average of non-missing morning and/or evening assessments of straining score from the SBMs reported by the participants on that specific day. LSM and SE were calculated using ANCOVA method.

    Measured: Baseline (14-day prior to randomization and up to randomization) to Week 4

  4. Change From Baseline (CFB) in 4-week Abdominal Bloating Daytime Symptoms Based on Evening Assessment

    Participants recorded their assessment of abdominal bloating in the evening eDiary. Participants answered the question: How big and full did your tummy feel? on a scale, where: 0=none, 1=a tiny bit, 2=a little, 3=medium or 4=very, with a higher score indicating more severe bloating. Baseline value was the average of values collected 14 days before randomization. The 4-week daytime abdominal bloating symptoms were calculated as the average of non-missing scores reported in the evening eDiary during the treatment period. Change from Baseline was calculated as the 4-week daytime abdominal bloating score during the treatment period - daytime abdominal bloating score at baseline. A negative change from Baseline indicates improvement. LSM and SE were calculated using ANCOVA method.

    Measured: Baseline (14-day prior to randomization) to Week 4

  5. Change From Baseline (CFB) in 4-week Overall Complete Spontaneous Bowel Movement Frequency Rate (CSBM/Week) During the Treatment Period

    SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. A CSBM was an SBM that was associated with a sense of complete evacuation. Participants recorded their assessment of the sensation of incomplete evacuation for each BM in the morning and evening eDiary. The 4-week overall CSBM frequency rate was calculated as [total number of CSBMs in the analysis period/number of days in the analysis period]*7). Baseline value was based on values collected 14 days before randomization and up to randomization. Change from Baseline was calculated as the CSBM frequency rate during the 4-week treatment period - CSBM frequency rate at baseline. A positive change from Baseline indicates improvement. LSM and SE were calculated using ANCOVA method.

    Measured: Baseline (14-day prior to randomization and up to randomization) to Week 4

  6. Change From Baseline in 4-week Fecal Incontinence Daytime Symptoms Based on Evening Assessment

    Participants recorded the presence of incontinence episodes in daytime daily since pre-treatment period (14-day prior to randomization) in the evening eDiary for participants randomized following protocol amendment #3. The 4-week daytime fecal incontinence was calculated as the mean of non-missing participant scores reported in the evening eDiary during the Treatment Period. Baseline value was the average of values collected 14 days before randomization. Change from Baseline was calculated as the 4-week fecal incontinence daytime symptoms during the treatment period - fecal incontinence daytime symptoms at baseline. A negative change from Baseline indicates improvement.

    No data is reported for LIN 145 μg as it was an exploratory arm group.

    Measured: Baseline (14-day prior to randomization) to Week 4

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Sep 2015 (estimated)
  2. Study start3 Nov 2015
  3. Primary completion20 Apr 2018
  4. Study completion29 May 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
173 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02559570
Sponsor's protocol ID
LIN-MD-62
Status last verified
Jun 2019
First submitted
23 Sep 2015
Last updated
19 Jun 2019
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing LIN Dose A, LIN Dose B and LIN Dose C in people with Functional Constipation in Children Ages 6-17 Years, run by Forest Laboratories at 62 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Jun 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 62 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 14 May 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline (CFB) in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate During the Treatment Period (time frame: Baseline (14-day prior to randomization and up to randomization) to Week 4). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jun 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in